World Oncology Forum® 2015
Stop Cancer Now! Prevent the Preventable
Milan, Italy • 22-24 October 2015
Honorary Chairs: Michael B. Sporn (US) - Umberto Veronesi (IT)
Chairs: F. Cavalli (CH) - A. Costa (IT)
Scientific Programme Coordinators: A. Albini (IT) - A. De Censi (IT)
The Stop Cancer Now! Appeal was launched by the participants of the first World Oncology Forum held in Lugano in October 2012.
Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world.
The annual number of new cancer cases is expected to double over 25 years, and to reach 22 million by 2030.
A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing knowledge on cancer control and by implementing programs for tobacco control, vaccination (for liver and cervical cancers), and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake. Clinicians, public health professionals, and policy makers can play an active role in accelerating the application of such interventions globally.
The experts who have been selected to attend the 2015 World Oncology Forum in Milan, will discuss the topic “Prevent the Preventable” with the only exception of tobacco and smoking.
Key note lectures on the role of microbiota and immune system, infection, inflammation, preventive therapy for cancer, will be presented for discussion.
Special attention will be devoted to the effect of nutrition on cancer prevention and recurrence, with particular emphasis on topics related to diet, obesity and cancer risk. The final aim will be the dissemination of updated information to the media and general public.
The WOF is held in collaboration with:
under the patronage of:
with the support of:
and under the auspices of:
Most of the speaker's presentation slides are available here
Please, be aware that the slides are restricted to ClubESO members only.
We invite you to subscribe (free-of-charge) to ClubESO at www.eso.net
B. Bonanni, C. Brisken, P. Bruzzi, Y. Cui, G.P. Dotto, L. Licitra, R. Marti, E. Negri, U. Pastorino, P.G. Pelicci, E. Riboli, A. Vermorken, A. Viola, D. Zaridze
Adriana Albini, Fondazione Multimedica Onlus, Polo Scientifico e Tecnologico, Milano, Italia
Melina Arnold, International Agency for Research on Cancer (WHO/IARC), Lyon, France
Bernardo Bonanni, Istituto Europeo di Oncologia, Milano, Italy
Cathrin Brisken, ISREC, School of Life Sciences, Lausanne, Switzerland
Paolo Bruzzi, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
Franco Cavalli, European School of Oncology, Bellinzona, Switzerland
Alberto Costa, European School of Oncology, Milano, Italy
Yali Cui, Northwest University, Xi’an, China
Jack Cuzick, Wolfson Institute of Prevention Medicine, London, United Kingdom
Andrea De Censi, E.O. Ospedali Galliera, Genova, Italy
G. Paolo Dotto, University of Lausanne, Epalinges, Switzerland
Leslie Ford, National Cancer Institute, Rockville, USA
Margaret Foti, American Association for Cancer Research, Philadelphia, USA
Silvia Franceschi, International Agency for Research on Cancer (WHO/IARC), Lyon, France
Virgil Craig Jordan, University of Texas M.D. Anderson Cancer Center, Houston, USA
Lisa Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Alberto Mantovani, Istituto Clinico Humanitas, Rozzano, Italy
Rolf Marti, Swiss Cancer League, Bern, Switzerland
Eva Negri, Istituto Mario Negri, Milano, Italy
Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Pier Giuseppe Pelicci, Istituto Europeo di Oncologia, Milano, Italy
Michael Pollak, Mc Gill University and Jewish General Hospital, Montreal, Canada
You-Lin Qiao, Chinese Academy of Medical Sciences & Peking Union Medical C, Beijing, China
Elio Riboli, Imperial College London, United Kingdom
Michael Sporn, Dartmouth Medical School, Hanover, USA
Giorgio Trinchieri, Center for Cancer Research, NCI, NIH, Bethesda, USA
Alphons Vermorken, Northwest University, Xi’an, China
Umberto Veronesi, Istituto Europeo di Oncologia, Milano, Italy
Paolo Vineis, Imperial College London, United Kingdom
Antonella Viola, Università di Padova, Italy
Christopher Wild, International Agency for Research on Cancer (WHO/IARC), Lyon France
David Zaridze, Blokhin Cancer Research Centre, Moscow, Russia
Clin Cancer Res. 2016
May 24. pii: clincanres.0695.2016.
CANCER PREVENTION AND INTERCEPTION: A NEW ERA FOR CHEMOPREVENTIVE APPROACHES
Albini A. (1), DeCensi A. (2), Cavalli F. (3), Costa A. (4)
(1) Vascular Biology, Multimedica IRCCS firstname.lastname@example.org.
(2) Medical Oncology, Galliera Hospital.
(3) Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI).
(4) Research division, European School of Oncology.
At several recent, internationally attended scientific meetings, including the American Association for Cancer Research (AACR)'s "Shaping the Future of Cancer Prevention: A Roadmap for Integrative Cancer Science and Public Health" summit in Leesburg (VA) and the AACR Annual Meeting in New Orleans, the focus on cancer prevention to reduce cancer deaths was extensively discussed with renewed attention and emphasis. Cancer prevention should be actively proposed even to healthy individuals, and not just to individuals with high cancer risk. We discuss evaluation of a high cancer risk versus the relatively low risk for side effects of chemopreventive agents. The concept of cancer interception, which is halting transformed cells from becoming malignant cancers, should be adopted for cancer prevention. Potential prevention/interception actions include: adopting healthy life style and avoiding carcinogens, repressing inflammation and pathological angiogenesis, controlling metabolism, correcting insulin resistance and other metabolic alterations. Current drugs with limited toxicity that can be repurposed to reduce cancer incidence. Aspirin is now being recommended for prevention of colorectal cancer and prevents other neoplasms as well. Metformin and beta blockers could be valuable for reducing pancreatic and breast cancer onset. Based on the evaluation of cancer risk, we here call for personalized approaches for cancer prevention and preventive interception and we envisage a list of measures and potential guidelines for preventive and interceptive strategies to reduce cancer burden. Investment into translational research to bring these approaches into public health policies and in the clinic is urgently needed.
Copyright ©2016, American Association for Cancer Research.